$CBLL

TPG GP A, LLC sold $4.1M of CBLL (indirect holdings)

TPG GP A, LLC sold 202,368 indirectly-held shares of Ceribell, Inc. (CBLL) at $20.12 ($4.07M total) on 2026-06-26.

Original reporting
SEC EDGAR · TPG GP A, LLC
Published Jun 30, 2026, 8:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CBLL
Neutral
medium confidence
Mentioned
$CBLL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or other disclosures, but this single sale does not, by itself, indicate a new operational or financial development.

02

Market read

A $4.07M open-market sale by an indirect holder is disclosed; it may slightly pressure sentiment but lacks a fundamental catalyst.

03

What to watch

No context is provided on total insider ownership changes beyond the post-transaction share count; without additional filings (buys, other holders, or follow-on news), the signal is weak.

Relevance 6/10Novelty 5/10Timing: Filed 2026-06-30; transaction dated 2026-06-26.

Background

SEC Form 4 insider transaction for Ceribell, Inc. (CBLL) reported by TPG GP A, LLC as an indirect holder.

Company-level read

Ticker impact

$CBLLNeutralMedium confidence
Context

TPG GP A, LLC filed a Form 4 showing an open-market sale of 202,368 CBLL shares for about $4.07M on 2026-06-26.

Expected impact

Low near-term impact; any effect is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a sizable dollar amount, but it is an indirect holding and explicitly states no 10b5-1 plan, which reduces interpretability rather than confirming a fundamental shift.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide driver.

None indicated.

None indicated.

Counterpoint

The sale could be liquidity/portfolio rebalancing rather than a bearish view, especially given it’s an indirect holding and lacks a stated 10b5-1 plan.

Key entities

  • Ceribell, Inc.

    CBLL, the company whose shares were sold in the reported Form 4 transaction.

  • TPG GP A, LLC

    Reported the open-market sale of CBLL shares as an indirect holding.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

$CBLLMedAI 8/10

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.

$CBLLHigh

Ceribell Reports Second Quarter 2026 Financial Results

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor